why choose us

First received: November 21, 2022

Clinical Trial: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Study Status: Completed

Recruit Status: RECRUITING

Condition: Recurrent Lung Non-Small Cell Carcinoma

Study Type: INTERVENTIONAL


Official Title: Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunot

Brief Summary: This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent).Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow.Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the…

Read more